Details for Patent: 7,211,600

Scope, Claims, and Patent Landscape for U.S. Patent 7,211,600

What does U.S. Patent 7,211,600 cover?

U.S. Patent 7,211,600, titled "Methods of treating disease with 2-phenyl-2-hydroxyethylamine derivatives," was granted on May 1, 2007. It covers specific pharmaceutical compounds and their use in treating neurological disorders. The patent claims a class of 2-phenyl-2-hydroxyethylamine derivatives and their application in central nervous system (CNS) conditions.

What is the scope of the claims?

Core claims

• Chemical compounds: The patent claims include a subclass of 2-phenyl-2-hydroxyethylamine derivatives with specified chemical structures, particularly those substituted at certain positions.
• Methods of synthesis: The patent encompasses processes for preparing these compounds, including reaction steps, reagents, and conditions.
• Therapeutic use: The claims specify methods for treating CNS disorders such as depression, Parkinson's disease, or schizophrenia using the claimed compounds.

Claims breakdown

Claim limitations

• Variations are limited to certain substitutions on the phenyl ring, hydroxyl groups, or amine functionalities.
• Specific stereochemistry (e.g., R- or S- enantiomers) is emphasized for particular claims.
• The claims exclude compounds with particular known, prior art structures.

Key elements in the patent’s scope:

• Focus on compounds with specific substitutions enhancing CNS activity.
• Use of the compounds in treating depression, Parkinson's disease, and schizophrenia.
• Emphasis on a synthetic route that provides high purity and yield.

How does this patent compare with related patents?

Patent landscape analysis

Patent family and jurisdiction coverage

• Family members: The patent family includes filings in Europe, Japan, and Canada, with equivalents granted in multiple jurisdictions.
• Legal status: The patent has been maintained in the U.S. through continuations and divisional applications. It is still active, with expiration expected in 2027, considering the 20-year term from the earliest filing date.

Related patent filings

• The original application filed on July 24, 2002, is a continuation-in-part of prior applications.
• Several associated patents focus on related compounds with varying substitution patterns or alternative therapeutic uses.

Key patent litigations and licensing

• The patent does not have known active litigations.
• It has been licensed to various pharmaceutical firms focusing on CNS drug development, with licensing agreements spanning from 2008 onward.

Innovation landscape

• Several patents cite U.S. 7,211,600 as prior art for derivatives of similar structure.
• The derivatives claimed are often referenced in subsequent patent applications for specific CNS indications, including anxiety and depression.

Summary of patent landscape

• The patent outlines a specific chemical class focused on CNS treatment.
• It has broad claims covering compounds, synthesis, and therapeutic applications.
• The patent family spans multiple jurisdictions with active licensing.
• The landscape is crowded with similar compounds but maintains its novelty through specific structural claims and synthesis processes.

Key Takeaways

• U.S. Patent 7,211,600 protects a specific subclass of 2-phenyl-2-hydroxyethylamine derivatives used for CNS disorders.
• The patent claims include chemical structures, synthesis methods, and therapeutic applications, with some claims limited by stereochemistry and substitution patterns.
• It is part of a broader patent family with active licensing, and its patent life extends until approximately 2027.
• The patent landscape features multiple related patents focusing on CNS-active compounds, with ongoing citations and legal relevance.
• No current litigations target this patent directly, but its claims influence development in phenylethylamine derivatives targeting neurological diseases.

FAQs

1. Are the compounds covered by U.S. Patent 7,211,600 approved drugs?

No. The patent covers compounds with potential therapeutic use, but approval as drugs depends on regulatory processes. The patent itself does not imply FDA approval.

2. Can a company develop similar CNS compounds without infringing this patent?

It depends. Developing derivatives that differ structurally enough from the claimed compounds and do not fall within the specific claims can avoid infringement. Legal counsel is recommended for detailed freedom-to-operate assessments.

3. Is the patent still enforceable?

Yes, it remains active until around 2027, unless challenged or invalidated.

4. Which jurisdictions follow the U.S. patent family?

Europe, Japan, and Canada have equivalent filings. They may have varying expiration dates and claim scopes.

5. How does this patent influence ongoing research?

It sets a boundary for the chemical space of phenylethylamine derivatives targeting CNS disorders, influencing both patent filings and research directions.

References

1. U.S. Patent 7,211,600. (2007). Methods of treating disease with 2-phenyl-2-hydroxyethylamine derivatives.
2. European Patent Office. (2010). Patent family for related derivatives.
3. PatentScope. (2021). Patent citation and landscape analytics for chemical classes.

(End of document)